Reporting of adverse events ONLY

Patients should always seek the advice of a doctor or pharmacist in case of adverse events.

If you wish to report an adverse event to ELC Group s.r.o., please find the contact information below:

+420 224 910 672

(from 09.00-17.30 CET)

+420 226 251 459

(non-stop 24/7)

To contact us about any other issue please call:

+420 22 491 0000or our regional offices.

Hlášení nežádoucích príhod

Pacienti by meli vždy požádat o radu svého lékare nebo lékárníka v prípade výskytu nežádoucích príhod.

Pokud chcete nahlásit nežádoucí príhodu spolecnosti ELC Group s r.o., prosím využijte kontaktních údaju níže:

+420 224 910 672

(09.00-17.30 CET)

+420 226 251 459

(non-stop 24/7)

Pro záležitosti, které se netýkaji farmakovigilance, kontaktujte prosím recepci:

+420 22 491 0000 nebo naše další pobočky.

Pharmaceutical regulatory affairs specialist ELC Group opens new office in Mumbai

Cambridge, UK, March 6 2012 – ELC GROUP, the pan-European pharmaceutical regulatory affairs organisation, today announces that it has opened a new office in Mumbai, India. The Mumbai operation will be staffed with a senior regulatory affairs team and expands ELC Group’s presence in India, adding to the Group’s successful regional base in Gujarat.

The newly-opened Mumbai office – located in the world’s largest pharmaceutical hub – is being headed by Pooja (Rai) Telavane, General Manager, Regulatory Affairs. Pooja Rai has over 10 years’ high-level industry experience in pharmaceuticals and regulatory affairs, and joins from her role as Senior Manager, Regulatory Affairs at Reliance Life Science. Pooja Rai is currently studying for a Masters (MSc) in Clinical Research and Regulatory Affairs.

From the Mumbai base, Pooja Rai will be responsible for driving continued uptake of ELC Group’s specialist regulatory affairs consulting and commercialisation services across fast-growing markets including India, China, South Korea, Malaysia and Singapore. Core specialisations will include support for clinical trials, bioequivalence studies, and delivery of RA services for the Gulf Cooperation Council region and South East Asia. The new Mumbai operation comprises a core team of senior RA staff for pharmaceuticals drugs, plus highly experienced business development teams focused on REACH, medical devices and pharmaceuticals. ELC Group recently announced the formal opening of a new global headquarters in Cambridge, UK, following a year of exceptional revenue growth.

Commenting on the Mumbai office opening, Marco Rubinstein, CEO of ELC Group said: “With over 25 global headquarters of our clients located in Mumbai and ambitious plans for ongoing growth, this latest regional expansion is a natural and strategic fit for us.” He added: “We are opening this new base with a very strong specialist team, and will be quickly looking to expand our personnel with the most experienced RA specialists that this booming region can offer.”

ELC Group helps pharmaceutical clients expedite time-to-market through a broad range of development capabilities, integrated advanced technologies, regulatory affairs consulting, and commercialisation services. ELC Group delivers its customised solutions through four core business segments: Regulatory Affairs Services; Medical Devices; EU REACH (Registration, Evaluation and Authorisation of Chemicals) Regulation Services; and Corporate Languages Solutions (Translations, Design, DTP, Localisation).